Article Versions Notes

Reverchon F, Guillard C, Mollet L, Auzou P, Gosset D, Madouri F, Valéry A, Menuet A, Ozsancak C, Pallix-Guyot M, et al. T Lymphocyte Serotonin 5-HT₇ Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. Biomedicines. 2022; 10(10):2418. https://doi.org/10.3390/biomedicines10102418

Reverchon, Flora, Colleen Guillard, Lucile Mollet, Pascal Auzou, David Gosset, Fahima Madouri, Antoine Valéry, Arnaud Menuet, Canan Ozsancak, Maud Pallix-Guyot, and et al. 2022. "T Lymphocyte Serotonin 5-HT₇ Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients" Biomedicines 10, no. 10: 2418. https://doi.org/10.3390/biomedicines10102418

Reverchon, F., Guillard, C., Mollet, L., Auzou, P., Gosset, D., Madouri, F., Valéry, A., Menuet, A., Ozsancak, C., Pallix-Guyot, M., & Morisset-Lopez, S. (2022). T Lymphocyte Serotonin 5-HT₇ Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. Biomedicines, 10(10), 2418. https://doi.org/10.3390/biomedicines10102418